Categories AlphaGraphs, Earnings, Other Industries

Mylan N.V. Q4 2017 earnings snapshot

Generic and specialty pharmaceuticals company Mylan reported a 41.4% plunge in its fourth quarter earnings to $244.3 million, impacted by the recognition of a tax benefit in the prior year of $192.6 million as compared to tax expense in the current period of $82.8 million, including the provisional impact of $128.6 million related to the enactment of the Tax Cuts and Jobs Act of 2017.

Adjusted earnings per share declined 8.9% to $1.43 from $1.57 in the same period in 2016.

Revenue declined marginally by 0.8% to $3.23 billion from $3.26 billion a year earlier. North American third party net sales declined 17%, while excluding the decline in sales of the EpiPen, this segment slid 8%. However, Europe segment third party net sales jumped 16% to $1.07 billion.

Outlook

For 2018, Mylan expects total revenue in the range of $11.75 billion to $13.25 billion. Adjusted EPS is expected to be in the range of $5.20 to $5.60, the midpoint of which represents an increase of 18% versus 2017.

Mylan N.V. earnings

Most Popular

Important takeaways from Paychex’s (PAYX) Q2 2025 earnings report

Paychex Inc. (NASDAQ: PAYX), a leading provider of human resources and payroll services, reported better-than-expected revenue and profit for the second quarter of fiscal 2025, sending the stock higher soon

Lamb Weston’s (LW) challenges may not end soon, a few points to note

Shares of Lamb Weston Holdings, Inc. (NYSE: LW) turned red in mid-day trade on Friday. The stock has dropped 19% in the past one month. The company delivered disappointing results

CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%

Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top